Mesalamine and Memantine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mesalamine (mesalamine) and Memantine (memantine). Common drug interactions include autism spectrum disorder among females and abdominal pain upper among males.

The phase IV clinical study analyzes what interactions people have when they take Mesalamine and Memantine. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 28,053 Mesalamine users. Check the latest studies of Mesalamine.

What is Memantine?

Memantine has active ingredients of memantine. It is often used in alzheimer's disease. eHealthMe is studying from 10,266 Memantine users. Check the latest studies of Memantine.

On Jul, 15, 2026

34 people who take Mesalamine and Memantine together, and have interactions are studied.

Mesalamine and Memantine drug interactions.

What are the common drug interactions of Mesalamine and Memantine, by gender? *:

female:

Autism spectrum disorder (developmental disabilities that can cause significant social, communication and behavioural challenges)
Diarrhoea
Ear infection
Fungal infection
Gastric infection (infection of stomach)
Gastrointestinal viral infection (virus infection of gastrointestinal tract)
Haemorrhage (bleeding)
Influenza
Mouth ulceration (mouth ulcers)
Polyp

male:

Abdominal pain upper
Blood potassium decreased
Nephrolithiasis (calculi in the kidneys)
Orthostatic hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up)
Repetitive speech
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Terminal state (the transitional states between life and biological death)
Urinary tract disorder
Weight decreased
White blood cell count increased

What are the common drug interactions of Mesalamine and Memantine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Confusional state
Death
Injection site pain
Nephrolithiasis (calculi in the kidneys)
Repetitive speech
Respiratory failure (inadequate gas exchange by the respiratory system)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Terminal state (the transitional states between life and biological death)
Urinary tract disorder
Weight decreased

What are the existing conditions these people have? *

Parkinson's Disease: 5 people, 14.71%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 11.76%
Delusion (a false belief or opinion): 4 people, 11.76%
Memory Loss: 4 people, 11.76%
Hallucinations (sensations that appear real but are created by your mind): 4 people, 11.76%
Muscle Spasms (muscle contraction): 3 people, 8.82%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 8.82%
Immunodeficiency Common Variable: 3 people, 8.82%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 8.82%
Respiratory Tract Congestion (blockage on respiratory system): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and Memantine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously